Actively Recruiting
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
Led by James Reynolds · Updated on 2025-12-02
35
Participants Needed
1
Research Sites
448 weeks
Total Duration
On this page
Sponsors
J
James Reynolds
Lead Sponsor
C
Case Western Reserve University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
CONDITIONS
Official Title
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hemoglobin greater than 12 g/dl
- Healthy, non-pregnant adults aged 18 to 35 with no blood disorders or diseases affecting oxygen delivery
- Active blood and platelet donors are preferred participants familiar with blood withdrawal and reinfusion
You will not qualify if you...
- Pregnant, breastfeeding, or unwilling to avoid pregnancy during the study
- Anatomic abnormalities increasing risks with vascular catheter placement
- Chronic diseases requiring medication for heart, lungs, kidneys, liver, or acute/chronic conditions making participation unsuitable
- Recent antibiotic therapy
- Use of phosphodiesterase 5 inhibitors within 24 hours before donation or transfusion
- Use of blood thinners such as warfarin, heparin, clopidogrel, enoxaparin, or dalteparin
- Use of allopurinol, beta-blockers, tricyclic antidepressants, meperidine, CNS agents, or nitrates
- Long-term antihistamine use; occasional antihistamine use considered case-by-case
- Blood pressure above 130/90 mm Hg; mild hypertension acceptable
- Heart rate outside 50-100 beats per minute or pathological irregularity; lower pulse acceptable for endurance trainers
- Blood coagulation disorders, congenital methemoglobinemia, or familial hemoglobinopathies impacting oxygen delivery
- Any illness increasing study risks
- Previous blood product treatment for acute conditions evaluated case-by-case
- Acute or chronic diseases impacting oxygen delivery
- Reduced lung capacity
- Difficulty with face mask use or inhalation for 2-3 hours due to claustrophobia, asthma, allergies, or sensitive skin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
Research Team
J
James D Reynolds, PhD
CONTACT
S
Sindhuja Senigarapu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here